Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous EBV-specific CTLs in SLE
NCT02677688Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Jan 2016
- Primary completion
- Jul 2021
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous Epstein-Barr virus-specific cytotoxic T lymphocytes in systemic lupus erythematosus (SLE), sponsored by CHU de Nantes. Started Jan 2016; status: terminated.
02
Drugs
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02677688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677688.